AngioDynamics reports PRESERVE trial results for NanoKnife system

AngioDynamics has reported two-year data from the PRESERVE pivotal trial, showing durable outcomes for the NanoKnife IRE system in treating intermediate-risk prostate cancer. The trial was conducted in 17 clinical centres, in partnership with the Society of Urologic Oncology Clinical Trials Consortium. The trial evaluated focal IRE using the NanoKnife system in 121 patients with intermediate-risk prostate cancer. Credit: NMK-Studio / Shutterstock.com. AngioDynamics has reported two-year findings from the PRESERVE pivotal trial, showing durable outcomes for the NanoKnife irreversible electroporation (IRE) system in treating intermediate-risk prostate cancer. The single-arm, prospective pivotal investigational device exemption (IDE) trial evaluated focal IRE using…

Source: Medical Device Network